Division of Rheumatology and Clinical Immunology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan.
Rheumatol Int. 2012 Nov;32(11):3691-4. doi: 10.1007/s00296-011-2118-1. Epub 2011 Sep 1.
We examined change in the antibody titre against pandemic influenza A/H1N1/2009 before and after vaccination in Japanese patients with rheumatoid arthritis. This observational study was conducted with the participation of five hospitals in Japan. A total of 89 patients with rheumatoid arthritis were included in this study. The seroprotection and seroresponse rates to vaccination with the pandemic influenza A/H1N1/2009 vaccine were analysed. The seroprotection rates prior to the vaccination were 5.6% in the Japanese patients with rheumatoid arthritis. The seroprotection rates after subcutaneous vaccination were 55.1%. The seroresponse rate after subcutaneous vaccination was 50.6% in the patients with rheumatoid arthritis. Both the seroprotection and seroresponse rates obtained after the vaccination with the pandemic influenza A/H1N1/2009 vaccine were low in Japanese patients with rheumatoid arthritis. We should realise that a vaccination against this newly emerged influenza virus may protect only half of the Japanese patients with rheumatoid arthritis in a real world.
我们研究了日本类风湿关节炎患者接种大流行性流感 A/H1N1/2009 疫苗前后针对大流行性流感 A/H1N1/2009 的抗体滴度变化。本观察性研究在日本的五家医院进行。共有 89 例类风湿关节炎患者纳入本研究。分析了接种大流行性流感 A/H1N1/2009 疫苗的血清保护率和血清反应率。接种前，日本类风湿关节炎患者的血清保护率为 5.6%。皮下接种后的血清保护率为 55.1%。类风湿关节炎患者皮下接种后的血清反应率为 50.6%。接种大流行性流感 A/H1N1/2009 疫苗后获得的血清保护率和血清反应率均较低。我们应该认识到，在现实世界中，这种新出现的流感病毒疫苗可能只能保护一半的日本类风湿关节炎患者。
